Implant Sciences (OTCQB:IMSC) Presentation
-
Upload
investorideascom -
Category
Investor Relations
-
view
555 -
download
0
description
Transcript of Implant Sciences (OTCQB:IMSC) Presentation
THE NEW STANDARD IN TRACE DETECTION
Corporate Overview
Glenn BolducPresident & CEO
Company Confidential 2
Safe Harbor StatementDuring today’s presentation, we will make certain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements.
Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Company Confidential 3
An American Security Innovator
Implant Sciences is proud to be contributing to the worldwide fight against terrorism
Company Confidential 4
About Implant Sciences (IMSC)Proven provider of explosives & drugs trace detection equipment
• Our systems detect microscopic amounts left behind after person handles explosives or drugs
• Global customer base, large U.S. opportunity• Over 2,000 systems sold in more than 50 countries• Strong cadre of industry veterans• Presence in government and corporate markets
Innovator in trace detection technology• Unmatched technology, new product• Strong IP portfolio: 17 patents, 6 pending
Company Confidential 5
The Challenge More bomb attacks, new targets
• Critical infrastructure• Public transportation
Changing tactics• Shoe bomber• Underwear bomber• Printer cartridge bomb
Different types of threats• “Home-grown” terrorism increasing• Smuggling and narco-terrorism
New answers are needed to fight the evolving threat
Company Confidential 6
Problems with Existing Methods
• Lack of privacy and dignity• Concerns over radioactive
materials
• Clogged security checkpoints• Operational availability• Growing security costs
Company Confidential 7
Implant Sciences’ Technology Patented technology
• inCal™ automatic internal calibration• Non-radioactive IMS analysis• Non-contact vortex collector
Engineered for the real world• Low maintenance, low TCO• Rapid clear-down• No rest breaks required• Identifies substances by name
“[The industry] will develop a non-contact (non-swabbing) sampling
approach which eliminates the inconsistencies that
plague manual swabbing and allows targets of varied
surface types, structures, and materials to be sampled efficiently.”
-Homeland Security Research Corporation
Company Confidential 8
Implant Sciences’ Vision Improving science with innovative IP
The non-contact sampling alternative• Screening with dignity• Integrated solutions to unclog
security checkpoints• Layered security approach
Homeland Security Research Corporation states that there is “no competitive explosives and narcotics trace detection modality on the
horizon” to compete with today’s trace detection systems.
Company Confidential 9
Implant Sciences’ Products Industry leading design
• No radioactive materials• Low operating expense• Rapid detection, fast clear-down• inCalTM fully automatic internal calibration
QS-H150 Handheld Explosives Trace Detector• Choice of non-contact or wipe sampling• Flexibility for Risk-Based Screening CONOPS
QS-B220 Desktop Explosives & Drugs Trace Detector• Small footprint ideal for crowded checkpoint• Drug detection capability opens new markets
Company Confidential 10
The New Standard in Trace Detection
Company Confidential 11
Global Presence in Various Applications
Over 2,000 systems sold in over 50 countries
Strong BRIC Presence
Africa, EU, & Mid-East growth
Focus on U.S. Penetration
Company Confidential 12
Growing Momentum for QS-B220Jan 2013 TSA Approval for Cargo Screening
Jul 2013 TSA Approval for Passenger and Baggage Screening
Sept 2013 STAC Approval for Cargo, Passenger, and Baggage Screening
Oct 2013 Added to TSA Qualified Products List for Cargo Screening
Oct 2013 Designated as Qualified Anti-Terrorism Technology by DHS
Feb 2014 Qualified Testing & Evaluation for TSA Checkpoint complete
Currently In final stage of TSA checkpoint qualification – OT&E (field trial)
Looking ahead… TSA Checkpoint and Baggage Qualification (expected June 2014)
Company Confidential 13
2012 2013 2014 2015 2016
Growing IMSC Market Opportunity
Aviation Security – 46%
Customs & Borders
Government
Public EventsSeaportsRailEducationCommercialMilitary and Police
ETD Market Segments
Source: IMS Research, and Management Estimates
Handheld Systems
Desktop Systems
Implant Sciences’ Market Opportunity
TSA Checkpoint and Baggage Qualification
Additional Int’l
Approva
ls
Focus on regulatory approvals grows IMSC opportunity.
ACSTLSTAC
350% market opportunity growth
2012-2106.
Pote
ntial
Pro
duct
Rev
enue
Company Confidential
Growth Strategy Expand U.S. market penetration
• Dedicated government sales team in place now• Negotiate IDIQ with TSA for checkpoint and baggage• Leverage QPL status with other agencies
Enhance international sales, marketing & distribution• STAC certification opens the European market• QPL with STAC provides greatly expanded global reach• Collaboration opportunity with other security providers
IP Leverage• New products, new technologies• Licensing• Development agreements
14
Company Confidential 15
High Profile Board of Directors/Advisors
Howard Safir (Board Member)• Former NYC Police Commissioner and Former NYC Fire Commissioner• Assistant Director of the DEA • Chief of the Witness Security Division, U.S. Marshals Service
Robert Liscouski (Board Member)• First Assistant Secretary for Infrastructure Protection at DHS• 11 years with the Diplomatic Security Service at the State Department• Director of Information Assurance for The Coca-Cola Company
Dr. Bill McGann (COO, Board Member)• Original developer of ETD technology at Ion Track, successfully sold to GE• Chief Technology Officer at GE Homeland Security• Strong TSA/TSL relationships
Mo McGowan (Advisor)• One of the founders of the Transportation Security Administration• Assistant Administrator for Security Operations• General Manager for Cargo and Supply Chain Security
Company Confidential 16
Made in USA
Implant Sciences currently employs 75 direct employees and an additional 10-20 through contract manufacturers
We source 95% of our inputs locally, affecting an additional 50-75 jobs
For every 45 incremental units, we can create another U.S. job
Company Confidential 17
Thank You
We welcome your questions and comments
COSD1402